Nkarta, Inc.
NKTXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | $0 | $0 |
| Operating income | −$122.0M | −$128.2M | −$131.7M | −$119.0M | −$86.4M | −$51.5M |
| Net income | −$104.1M | −$108.8M | −$117.5M | −$113.8M | −$86.1M | −$91.4M |
| Total assets | $404.2M | $501.2M | $378.9M | $472.9M | $273.9M | $337.6M |
| Total liabilities | $91.9M | $93.2M | $105.6M | $100.7M | $22.9M | $16.4M |
| Equity | $312.3M | $408.0M | $273.3M | $372.2M | $251.0M | $321.2M |
| EPS (diluted) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 | — |
| Shares out. | 71.0M | 49.4M | 48.9M | 33.0M | 32.8M | 32.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −33.3%
- Return on assets
- −25.8%
- Return on capital (ROCE)
- −31.9%
- Liabilities / assets
- 22.7%
- Debt / equity
- 0.29×
- Book value / share
- $4.40
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.54distress
- Accruals / assets
- −3.8%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2024-10-02NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
- Phase 1Active Not Recruitingreadout ~2025-03-31NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Phase 1/2Recruitingreadout ~2027-04A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- Phase 1/2Recruitingreadout ~2028-10A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- New Enterprise Associates 15, L.P.Activist (13D)May 19, 2026
- Tang Capital Management LlcPassive (13G)Feb 17, 2026
- Samsara Biocapital, L.P.Activist (13D)Nov 24, 2025
- Citadel Advisors LlcPassive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Commodore Capital LpPassive (13G)Feb 14, 2025
- Lsp 6 Holding C.V.Activist (13D)Feb 12, 2025
- Adage Capital Partners Gp, L.L.C.Passive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.2M | 5.9 | -2.1% |
| Apr 30, 2026 | 5.3M | 3.9 | -2.5% |
| Apr 15, 2026 | 5.4M | 9.7 | -2.3% |
| Mar 31, 2026 | 5.5M | 9.6 | +0.3% |
| Mar 13, 2026 | 5.5M | 7.4 | -5.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Other material eventMar 26, 2026
- Results of operationsMar 25, 2026
- Results of operationsNov 10, 2025
- Results of operationsAug 12, 2025
- Director / officer change · Shareholder vote · Regulation FD disclosureJun 6, 2025
- Results of operationsMay 14, 2025
- Results of operations · Costs from exit or disposal · Director / officer change · Other material eventMar 26, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.